PANHER study: a 20-year treatment outcome analysis from a multicentre observational study of HER2-positive advanced breast cancer patients from the real-world setting
Background: The evolution of therapeutic landscape of human epidermal growth factor receptor-2 (HER2)-positive breast cancer (BC) has led to an unprecedented outcome improvement, even if the optimal sequence strategy is still debated. To address this issue and to provide a picture of the advancement...
Guardado en:
| Autores principales: | , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , |
|---|---|
| Formato: | article |
| Lenguaje: | EN |
| Publicado: |
SAGE Publishing
2021
|
| Materias: | |
| Acceso en línea: | https://doaj.org/article/8be0edebe30b47389bcf83b804b70b94 |
| Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
| id |
oai:doaj.org-article:8be0edebe30b47389bcf83b804b70b94 |
|---|---|
| record_format |
dspace |
| spelling |
oai:doaj.org-article:8be0edebe30b47389bcf83b804b70b942021-12-01T23:34:02ZPANHER study: a 20-year treatment outcome analysis from a multicentre observational study of HER2-positive advanced breast cancer patients from the real-world setting1758-835910.1177/17588359211059873https://doaj.org/article/8be0edebe30b47389bcf83b804b70b942021-11-01T00:00:00Zhttps://doi.org/10.1177/17588359211059873https://doaj.org/toc/1758-8359Background: The evolution of therapeutic landscape of human epidermal growth factor receptor-2 (HER2)-positive breast cancer (BC) has led to an unprecedented outcome improvement, even if the optimal sequence strategy is still debated. To address this issue and to provide a picture of the advancement of anti-HER2 treatments, we performed a large, multicenter, retrospective study of HER2-positive BC patients. Methods: The observational PANHER study included 1,328 HER2-positive advanced BC patients treated with HER2 blocking agents since June 2000 throughout July 2020. Endpoints of efficacy were progression-free survival (PFS) and overall survival (OS). Results: Patients who received a first-line pertuzumab-based regimen showed better PFS ( p < 0.0001) and OS ( p = 0.004) than those receiving other treatments. Median PFS and mOS from second-line starting were 8 and 28 months, without significant differences among various regimens. Pertuzumab-pretreated patients showed a mPFS and a mOS from second-line starting not significantly affected by type of second line, that is, T-DM1 or lapatinib/capecitabine ( p = 0.80 and p = 0.45, respectively). Conversely, pertuzumab-naïve patients receiving second-line T-DM1 showed a significantly higher mPFS compared with that of patients treated with lapatinib/capecitabine ( p = 0.004). Median OS from metastatic disease diagnosis was higher in patients treated with trastuzumab-based first line followed by second-line T-DM1 in comparison to pertuzumab-based first-line and second-line T-DM1 ( p = 0.003), although these data might be partially influenced by more favorable prognostic characteristics of patients in the pre-pertuzumab era . No significant differences emerged when comparing patients treated with ‘old’ or ‘new’ drugs ( p = 0.43), even though differences in the length of the follow-up between the two cohorts should be taken into account. Conclusion: Our results confirmed a relevant impact of first-line pertuzumab-based treatment and showed lower efficacy of second-line T-DM1 in trastuzumab/pertuzumab pretreated, as compared with pertuzumab-naïve patients. Our findings may help delineate a more appropriate therapeutic strategy in HER2-positive metastatic BC. Prospective randomized trials addressing this topic are awaited.Laura PizzutiEriseld KrasniqiIsabella SperdutiMaddalena BarbaTeresa GamucciMaria MauriEnzo Maria VeltriIcro MeattiniRossana BerardiFrancesca Sofia Di LisaClara NatoliMirco PistelliLaura IezziEmanuela RisiNicola D’OstilioSilverio TomaoCorrado FicorellaKatia CannitaFerdinando RiccardiAlessandra CassanoEmilio BriaMaria Agnese FabbriMarco MazzottaGiacomo BarchiesiAndrea BotticelliGiuliana D’AuriaAnna CeribelliAndrea MichelottiAntonio RussoBeatrice Taurelli SalimbeniGiuseppina SarobbaFrancesco GiottaIda ParisRosa SaltarelliDaniele MarinelliDomenico CorsiElisabetta Maria CapomollaValentina SiniLuca MoscettiLucia MentucciaGiuseppe ToniniMimma RaffaeleLuca MarchettiMauro MinelliEnzo Maria RuggeriPaola ScavinaOlivia BacciuNello SalesiLorenzo LiviNicola TinariAntonino GrassadoniaAngelo Fedele ScintoRosalinda RossiMaria Rosaria ValerioElisabetta LanducciSimonetta StaniBeatrice FratiniMarcello Maugeri-SaccàMichele De TursiAngela MaioneDaniele SantiniArmando OrlandiVito LorussoEnrico CortesiGiuseppe SanguinetiPaola PinnaròFederico CappuzzoLorenza LandiClaudio BottiFederica TomaoSonia CappelliGiulia BonFabio PelleFlavia CavicchiElena FiorioJennifer FogliettaSimone ScagnoliPaolo MarchettiGennaro CilibertoPatrizia ViciSAGE PublishingarticleNeoplasms. Tumors. Oncology. Including cancer and carcinogensRC254-282ENTherapeutic Advances in Medical Oncology, Vol 13 (2021) |
| institution |
DOAJ |
| collection |
DOAJ |
| language |
EN |
| topic |
Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282 |
| spellingShingle |
Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282 Laura Pizzuti Eriseld Krasniqi Isabella Sperduti Maddalena Barba Teresa Gamucci Maria Mauri Enzo Maria Veltri Icro Meattini Rossana Berardi Francesca Sofia Di Lisa Clara Natoli Mirco Pistelli Laura Iezzi Emanuela Risi Nicola D’Ostilio Silverio Tomao Corrado Ficorella Katia Cannita Ferdinando Riccardi Alessandra Cassano Emilio Bria Maria Agnese Fabbri Marco Mazzotta Giacomo Barchiesi Andrea Botticelli Giuliana D’Auria Anna Ceribelli Andrea Michelotti Antonio Russo Beatrice Taurelli Salimbeni Giuseppina Sarobba Francesco Giotta Ida Paris Rosa Saltarelli Daniele Marinelli Domenico Corsi Elisabetta Maria Capomolla Valentina Sini Luca Moscetti Lucia Mentuccia Giuseppe Tonini Mimma Raffaele Luca Marchetti Mauro Minelli Enzo Maria Ruggeri Paola Scavina Olivia Bacciu Nello Salesi Lorenzo Livi Nicola Tinari Antonino Grassadonia Angelo Fedele Scinto Rosalinda Rossi Maria Rosaria Valerio Elisabetta Landucci Simonetta Stani Beatrice Fratini Marcello Maugeri-Saccà Michele De Tursi Angela Maione Daniele Santini Armando Orlandi Vito Lorusso Enrico Cortesi Giuseppe Sanguineti Paola Pinnarò Federico Cappuzzo Lorenza Landi Claudio Botti Federica Tomao Sonia Cappelli Giulia Bon Fabio Pelle Flavia Cavicchi Elena Fiorio Jennifer Foglietta Simone Scagnoli Paolo Marchetti Gennaro Ciliberto Patrizia Vici PANHER study: a 20-year treatment outcome analysis from a multicentre observational study of HER2-positive advanced breast cancer patients from the real-world setting |
| description |
Background: The evolution of therapeutic landscape of human epidermal growth factor receptor-2 (HER2)-positive breast cancer (BC) has led to an unprecedented outcome improvement, even if the optimal sequence strategy is still debated. To address this issue and to provide a picture of the advancement of anti-HER2 treatments, we performed a large, multicenter, retrospective study of HER2-positive BC patients. Methods: The observational PANHER study included 1,328 HER2-positive advanced BC patients treated with HER2 blocking agents since June 2000 throughout July 2020. Endpoints of efficacy were progression-free survival (PFS) and overall survival (OS). Results: Patients who received a first-line pertuzumab-based regimen showed better PFS ( p < 0.0001) and OS ( p = 0.004) than those receiving other treatments. Median PFS and mOS from second-line starting were 8 and 28 months, without significant differences among various regimens. Pertuzumab-pretreated patients showed a mPFS and a mOS from second-line starting not significantly affected by type of second line, that is, T-DM1 or lapatinib/capecitabine ( p = 0.80 and p = 0.45, respectively). Conversely, pertuzumab-naïve patients receiving second-line T-DM1 showed a significantly higher mPFS compared with that of patients treated with lapatinib/capecitabine ( p = 0.004). Median OS from metastatic disease diagnosis was higher in patients treated with trastuzumab-based first line followed by second-line T-DM1 in comparison to pertuzumab-based first-line and second-line T-DM1 ( p = 0.003), although these data might be partially influenced by more favorable prognostic characteristics of patients in the pre-pertuzumab era . No significant differences emerged when comparing patients treated with ‘old’ or ‘new’ drugs ( p = 0.43), even though differences in the length of the follow-up between the two cohorts should be taken into account. Conclusion: Our results confirmed a relevant impact of first-line pertuzumab-based treatment and showed lower efficacy of second-line T-DM1 in trastuzumab/pertuzumab pretreated, as compared with pertuzumab-naïve patients. Our findings may help delineate a more appropriate therapeutic strategy in HER2-positive metastatic BC. Prospective randomized trials addressing this topic are awaited. |
| format |
article |
| author |
Laura Pizzuti Eriseld Krasniqi Isabella Sperduti Maddalena Barba Teresa Gamucci Maria Mauri Enzo Maria Veltri Icro Meattini Rossana Berardi Francesca Sofia Di Lisa Clara Natoli Mirco Pistelli Laura Iezzi Emanuela Risi Nicola D’Ostilio Silverio Tomao Corrado Ficorella Katia Cannita Ferdinando Riccardi Alessandra Cassano Emilio Bria Maria Agnese Fabbri Marco Mazzotta Giacomo Barchiesi Andrea Botticelli Giuliana D’Auria Anna Ceribelli Andrea Michelotti Antonio Russo Beatrice Taurelli Salimbeni Giuseppina Sarobba Francesco Giotta Ida Paris Rosa Saltarelli Daniele Marinelli Domenico Corsi Elisabetta Maria Capomolla Valentina Sini Luca Moscetti Lucia Mentuccia Giuseppe Tonini Mimma Raffaele Luca Marchetti Mauro Minelli Enzo Maria Ruggeri Paola Scavina Olivia Bacciu Nello Salesi Lorenzo Livi Nicola Tinari Antonino Grassadonia Angelo Fedele Scinto Rosalinda Rossi Maria Rosaria Valerio Elisabetta Landucci Simonetta Stani Beatrice Fratini Marcello Maugeri-Saccà Michele De Tursi Angela Maione Daniele Santini Armando Orlandi Vito Lorusso Enrico Cortesi Giuseppe Sanguineti Paola Pinnarò Federico Cappuzzo Lorenza Landi Claudio Botti Federica Tomao Sonia Cappelli Giulia Bon Fabio Pelle Flavia Cavicchi Elena Fiorio Jennifer Foglietta Simone Scagnoli Paolo Marchetti Gennaro Ciliberto Patrizia Vici |
| author_facet |
Laura Pizzuti Eriseld Krasniqi Isabella Sperduti Maddalena Barba Teresa Gamucci Maria Mauri Enzo Maria Veltri Icro Meattini Rossana Berardi Francesca Sofia Di Lisa Clara Natoli Mirco Pistelli Laura Iezzi Emanuela Risi Nicola D’Ostilio Silverio Tomao Corrado Ficorella Katia Cannita Ferdinando Riccardi Alessandra Cassano Emilio Bria Maria Agnese Fabbri Marco Mazzotta Giacomo Barchiesi Andrea Botticelli Giuliana D’Auria Anna Ceribelli Andrea Michelotti Antonio Russo Beatrice Taurelli Salimbeni Giuseppina Sarobba Francesco Giotta Ida Paris Rosa Saltarelli Daniele Marinelli Domenico Corsi Elisabetta Maria Capomolla Valentina Sini Luca Moscetti Lucia Mentuccia Giuseppe Tonini Mimma Raffaele Luca Marchetti Mauro Minelli Enzo Maria Ruggeri Paola Scavina Olivia Bacciu Nello Salesi Lorenzo Livi Nicola Tinari Antonino Grassadonia Angelo Fedele Scinto Rosalinda Rossi Maria Rosaria Valerio Elisabetta Landucci Simonetta Stani Beatrice Fratini Marcello Maugeri-Saccà Michele De Tursi Angela Maione Daniele Santini Armando Orlandi Vito Lorusso Enrico Cortesi Giuseppe Sanguineti Paola Pinnarò Federico Cappuzzo Lorenza Landi Claudio Botti Federica Tomao Sonia Cappelli Giulia Bon Fabio Pelle Flavia Cavicchi Elena Fiorio Jennifer Foglietta Simone Scagnoli Paolo Marchetti Gennaro Ciliberto Patrizia Vici |
| author_sort |
Laura Pizzuti |
| title |
PANHER study: a 20-year treatment outcome analysis from a multicentre observational study of HER2-positive advanced breast cancer patients from the real-world setting |
| title_short |
PANHER study: a 20-year treatment outcome analysis from a multicentre observational study of HER2-positive advanced breast cancer patients from the real-world setting |
| title_full |
PANHER study: a 20-year treatment outcome analysis from a multicentre observational study of HER2-positive advanced breast cancer patients from the real-world setting |
| title_fullStr |
PANHER study: a 20-year treatment outcome analysis from a multicentre observational study of HER2-positive advanced breast cancer patients from the real-world setting |
| title_full_unstemmed |
PANHER study: a 20-year treatment outcome analysis from a multicentre observational study of HER2-positive advanced breast cancer patients from the real-world setting |
| title_sort |
panher study: a 20-year treatment outcome analysis from a multicentre observational study of her2-positive advanced breast cancer patients from the real-world setting |
| publisher |
SAGE Publishing |
| publishDate |
2021 |
| url |
https://doaj.org/article/8be0edebe30b47389bcf83b804b70b94 |
| work_keys_str_mv |
AT laurapizzuti panherstudya20yeartreatmentoutcomeanalysisfromamulticentreobservationalstudyofher2positiveadvancedbreastcancerpatientsfromtherealworldsetting AT eriseldkrasniqi panherstudya20yeartreatmentoutcomeanalysisfromamulticentreobservationalstudyofher2positiveadvancedbreastcancerpatientsfromtherealworldsetting AT isabellasperduti panherstudya20yeartreatmentoutcomeanalysisfromamulticentreobservationalstudyofher2positiveadvancedbreastcancerpatientsfromtherealworldsetting AT maddalenabarba panherstudya20yeartreatmentoutcomeanalysisfromamulticentreobservationalstudyofher2positiveadvancedbreastcancerpatientsfromtherealworldsetting AT teresagamucci panherstudya20yeartreatmentoutcomeanalysisfromamulticentreobservationalstudyofher2positiveadvancedbreastcancerpatientsfromtherealworldsetting AT mariamauri panherstudya20yeartreatmentoutcomeanalysisfromamulticentreobservationalstudyofher2positiveadvancedbreastcancerpatientsfromtherealworldsetting AT enzomariaveltri panherstudya20yeartreatmentoutcomeanalysisfromamulticentreobservationalstudyofher2positiveadvancedbreastcancerpatientsfromtherealworldsetting AT icromeattini panherstudya20yeartreatmentoutcomeanalysisfromamulticentreobservationalstudyofher2positiveadvancedbreastcancerpatientsfromtherealworldsetting AT rossanaberardi panherstudya20yeartreatmentoutcomeanalysisfromamulticentreobservationalstudyofher2positiveadvancedbreastcancerpatientsfromtherealworldsetting AT francescasofiadilisa panherstudya20yeartreatmentoutcomeanalysisfromamulticentreobservationalstudyofher2positiveadvancedbreastcancerpatientsfromtherealworldsetting AT claranatoli panherstudya20yeartreatmentoutcomeanalysisfromamulticentreobservationalstudyofher2positiveadvancedbreastcancerpatientsfromtherealworldsetting AT mircopistelli panherstudya20yeartreatmentoutcomeanalysisfromamulticentreobservationalstudyofher2positiveadvancedbreastcancerpatientsfromtherealworldsetting AT lauraiezzi panherstudya20yeartreatmentoutcomeanalysisfromamulticentreobservationalstudyofher2positiveadvancedbreastcancerpatientsfromtherealworldsetting AT emanuelarisi panherstudya20yeartreatmentoutcomeanalysisfromamulticentreobservationalstudyofher2positiveadvancedbreastcancerpatientsfromtherealworldsetting AT nicoladostilio panherstudya20yeartreatmentoutcomeanalysisfromamulticentreobservationalstudyofher2positiveadvancedbreastcancerpatientsfromtherealworldsetting AT silveriotomao panherstudya20yeartreatmentoutcomeanalysisfromamulticentreobservationalstudyofher2positiveadvancedbreastcancerpatientsfromtherealworldsetting AT corradoficorella panherstudya20yeartreatmentoutcomeanalysisfromamulticentreobservationalstudyofher2positiveadvancedbreastcancerpatientsfromtherealworldsetting AT katiacannita panherstudya20yeartreatmentoutcomeanalysisfromamulticentreobservationalstudyofher2positiveadvancedbreastcancerpatientsfromtherealworldsetting AT ferdinandoriccardi panherstudya20yeartreatmentoutcomeanalysisfromamulticentreobservationalstudyofher2positiveadvancedbreastcancerpatientsfromtherealworldsetting AT alessandracassano panherstudya20yeartreatmentoutcomeanalysisfromamulticentreobservationalstudyofher2positiveadvancedbreastcancerpatientsfromtherealworldsetting AT emiliobria panherstudya20yeartreatmentoutcomeanalysisfromamulticentreobservationalstudyofher2positiveadvancedbreastcancerpatientsfromtherealworldsetting AT mariaagnesefabbri panherstudya20yeartreatmentoutcomeanalysisfromamulticentreobservationalstudyofher2positiveadvancedbreastcancerpatientsfromtherealworldsetting AT marcomazzotta panherstudya20yeartreatmentoutcomeanalysisfromamulticentreobservationalstudyofher2positiveadvancedbreastcancerpatientsfromtherealworldsetting AT giacomobarchiesi panherstudya20yeartreatmentoutcomeanalysisfromamulticentreobservationalstudyofher2positiveadvancedbreastcancerpatientsfromtherealworldsetting AT andreabotticelli panherstudya20yeartreatmentoutcomeanalysisfromamulticentreobservationalstudyofher2positiveadvancedbreastcancerpatientsfromtherealworldsetting AT giulianadauria panherstudya20yeartreatmentoutcomeanalysisfromamulticentreobservationalstudyofher2positiveadvancedbreastcancerpatientsfromtherealworldsetting AT annaceribelli panherstudya20yeartreatmentoutcomeanalysisfromamulticentreobservationalstudyofher2positiveadvancedbreastcancerpatientsfromtherealworldsetting AT andreamichelotti panherstudya20yeartreatmentoutcomeanalysisfromamulticentreobservationalstudyofher2positiveadvancedbreastcancerpatientsfromtherealworldsetting AT antoniorusso panherstudya20yeartreatmentoutcomeanalysisfromamulticentreobservationalstudyofher2positiveadvancedbreastcancerpatientsfromtherealworldsetting AT beatricetaurellisalimbeni panherstudya20yeartreatmentoutcomeanalysisfromamulticentreobservationalstudyofher2positiveadvancedbreastcancerpatientsfromtherealworldsetting AT giuseppinasarobba panherstudya20yeartreatmentoutcomeanalysisfromamulticentreobservationalstudyofher2positiveadvancedbreastcancerpatientsfromtherealworldsetting AT francescogiotta panherstudya20yeartreatmentoutcomeanalysisfromamulticentreobservationalstudyofher2positiveadvancedbreastcancerpatientsfromtherealworldsetting AT idaparis panherstudya20yeartreatmentoutcomeanalysisfromamulticentreobservationalstudyofher2positiveadvancedbreastcancerpatientsfromtherealworldsetting AT rosasaltarelli panherstudya20yeartreatmentoutcomeanalysisfromamulticentreobservationalstudyofher2positiveadvancedbreastcancerpatientsfromtherealworldsetting AT danielemarinelli panherstudya20yeartreatmentoutcomeanalysisfromamulticentreobservationalstudyofher2positiveadvancedbreastcancerpatientsfromtherealworldsetting AT domenicocorsi panherstudya20yeartreatmentoutcomeanalysisfromamulticentreobservationalstudyofher2positiveadvancedbreastcancerpatientsfromtherealworldsetting AT elisabettamariacapomolla panherstudya20yeartreatmentoutcomeanalysisfromamulticentreobservationalstudyofher2positiveadvancedbreastcancerpatientsfromtherealworldsetting AT valentinasini panherstudya20yeartreatmentoutcomeanalysisfromamulticentreobservationalstudyofher2positiveadvancedbreastcancerpatientsfromtherealworldsetting AT lucamoscetti panherstudya20yeartreatmentoutcomeanalysisfromamulticentreobservationalstudyofher2positiveadvancedbreastcancerpatientsfromtherealworldsetting AT luciamentuccia panherstudya20yeartreatmentoutcomeanalysisfromamulticentreobservationalstudyofher2positiveadvancedbreastcancerpatientsfromtherealworldsetting AT giuseppetonini panherstudya20yeartreatmentoutcomeanalysisfromamulticentreobservationalstudyofher2positiveadvancedbreastcancerpatientsfromtherealworldsetting AT mimmaraffaele panherstudya20yeartreatmentoutcomeanalysisfromamulticentreobservationalstudyofher2positiveadvancedbreastcancerpatientsfromtherealworldsetting AT lucamarchetti panherstudya20yeartreatmentoutcomeanalysisfromamulticentreobservationalstudyofher2positiveadvancedbreastcancerpatientsfromtherealworldsetting AT maurominelli panherstudya20yeartreatmentoutcomeanalysisfromamulticentreobservationalstudyofher2positiveadvancedbreastcancerpatientsfromtherealworldsetting AT enzomariaruggeri panherstudya20yeartreatmentoutcomeanalysisfromamulticentreobservationalstudyofher2positiveadvancedbreastcancerpatientsfromtherealworldsetting AT paolascavina panherstudya20yeartreatmentoutcomeanalysisfromamulticentreobservationalstudyofher2positiveadvancedbreastcancerpatientsfromtherealworldsetting AT oliviabacciu panherstudya20yeartreatmentoutcomeanalysisfromamulticentreobservationalstudyofher2positiveadvancedbreastcancerpatientsfromtherealworldsetting AT nellosalesi panherstudya20yeartreatmentoutcomeanalysisfromamulticentreobservationalstudyofher2positiveadvancedbreastcancerpatientsfromtherealworldsetting AT lorenzolivi panherstudya20yeartreatmentoutcomeanalysisfromamulticentreobservationalstudyofher2positiveadvancedbreastcancerpatientsfromtherealworldsetting AT nicolatinari panherstudya20yeartreatmentoutcomeanalysisfromamulticentreobservationalstudyofher2positiveadvancedbreastcancerpatientsfromtherealworldsetting AT antoninograssadonia panherstudya20yeartreatmentoutcomeanalysisfromamulticentreobservationalstudyofher2positiveadvancedbreastcancerpatientsfromtherealworldsetting AT angelofedelescinto panherstudya20yeartreatmentoutcomeanalysisfromamulticentreobservationalstudyofher2positiveadvancedbreastcancerpatientsfromtherealworldsetting AT rosalindarossi panherstudya20yeartreatmentoutcomeanalysisfromamulticentreobservationalstudyofher2positiveadvancedbreastcancerpatientsfromtherealworldsetting AT mariarosariavalerio panherstudya20yeartreatmentoutcomeanalysisfromamulticentreobservationalstudyofher2positiveadvancedbreastcancerpatientsfromtherealworldsetting AT elisabettalanducci panherstudya20yeartreatmentoutcomeanalysisfromamulticentreobservationalstudyofher2positiveadvancedbreastcancerpatientsfromtherealworldsetting AT simonettastani panherstudya20yeartreatmentoutcomeanalysisfromamulticentreobservationalstudyofher2positiveadvancedbreastcancerpatientsfromtherealworldsetting AT beatricefratini panherstudya20yeartreatmentoutcomeanalysisfromamulticentreobservationalstudyofher2positiveadvancedbreastcancerpatientsfromtherealworldsetting AT marcellomaugerisacca panherstudya20yeartreatmentoutcomeanalysisfromamulticentreobservationalstudyofher2positiveadvancedbreastcancerpatientsfromtherealworldsetting AT micheledetursi panherstudya20yeartreatmentoutcomeanalysisfromamulticentreobservationalstudyofher2positiveadvancedbreastcancerpatientsfromtherealworldsetting AT angelamaione panherstudya20yeartreatmentoutcomeanalysisfromamulticentreobservationalstudyofher2positiveadvancedbreastcancerpatientsfromtherealworldsetting AT danielesantini panherstudya20yeartreatmentoutcomeanalysisfromamulticentreobservationalstudyofher2positiveadvancedbreastcancerpatientsfromtherealworldsetting AT armandoorlandi panherstudya20yeartreatmentoutcomeanalysisfromamulticentreobservationalstudyofher2positiveadvancedbreastcancerpatientsfromtherealworldsetting AT vitolorusso panherstudya20yeartreatmentoutcomeanalysisfromamulticentreobservationalstudyofher2positiveadvancedbreastcancerpatientsfromtherealworldsetting AT enricocortesi panherstudya20yeartreatmentoutcomeanalysisfromamulticentreobservationalstudyofher2positiveadvancedbreastcancerpatientsfromtherealworldsetting AT giuseppesanguineti panherstudya20yeartreatmentoutcomeanalysisfromamulticentreobservationalstudyofher2positiveadvancedbreastcancerpatientsfromtherealworldsetting AT paolapinnaro panherstudya20yeartreatmentoutcomeanalysisfromamulticentreobservationalstudyofher2positiveadvancedbreastcancerpatientsfromtherealworldsetting AT federicocappuzzo panherstudya20yeartreatmentoutcomeanalysisfromamulticentreobservationalstudyofher2positiveadvancedbreastcancerpatientsfromtherealworldsetting AT lorenzalandi panherstudya20yeartreatmentoutcomeanalysisfromamulticentreobservationalstudyofher2positiveadvancedbreastcancerpatientsfromtherealworldsetting AT claudiobotti panherstudya20yeartreatmentoutcomeanalysisfromamulticentreobservationalstudyofher2positiveadvancedbreastcancerpatientsfromtherealworldsetting AT federicatomao panherstudya20yeartreatmentoutcomeanalysisfromamulticentreobservationalstudyofher2positiveadvancedbreastcancerpatientsfromtherealworldsetting AT soniacappelli panherstudya20yeartreatmentoutcomeanalysisfromamulticentreobservationalstudyofher2positiveadvancedbreastcancerpatientsfromtherealworldsetting AT giuliabon panherstudya20yeartreatmentoutcomeanalysisfromamulticentreobservationalstudyofher2positiveadvancedbreastcancerpatientsfromtherealworldsetting AT fabiopelle panherstudya20yeartreatmentoutcomeanalysisfromamulticentreobservationalstudyofher2positiveadvancedbreastcancerpatientsfromtherealworldsetting AT flaviacavicchi panherstudya20yeartreatmentoutcomeanalysisfromamulticentreobservationalstudyofher2positiveadvancedbreastcancerpatientsfromtherealworldsetting AT elenafiorio panherstudya20yeartreatmentoutcomeanalysisfromamulticentreobservationalstudyofher2positiveadvancedbreastcancerpatientsfromtherealworldsetting AT jenniferfoglietta panherstudya20yeartreatmentoutcomeanalysisfromamulticentreobservationalstudyofher2positiveadvancedbreastcancerpatientsfromtherealworldsetting AT simonescagnoli panherstudya20yeartreatmentoutcomeanalysisfromamulticentreobservationalstudyofher2positiveadvancedbreastcancerpatientsfromtherealworldsetting AT paolomarchetti panherstudya20yeartreatmentoutcomeanalysisfromamulticentreobservationalstudyofher2positiveadvancedbreastcancerpatientsfromtherealworldsetting AT gennarociliberto panherstudya20yeartreatmentoutcomeanalysisfromamulticentreobservationalstudyofher2positiveadvancedbreastcancerpatientsfromtherealworldsetting AT patriziavici panherstudya20yeartreatmentoutcomeanalysisfromamulticentreobservationalstudyofher2positiveadvancedbreastcancerpatientsfromtherealworldsetting |
| _version_ |
1718403998064574464 |